Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Loredana Santo, MD, Teru Hideshima, MD, PhD, Diana Cirstea, MD, Madhavi L Bandi, PhD, Erik A Nelson, PhD, Hiroshi Ikeda, MD, Sonia Vallet, MD, Samantha Pozzi, MD, Kishan Patel, Gullu Gorgun, PhD, Naoya Mimura, MD, Claire Fabre, MD, Yiguo Hu, PhD, Dharminder Chauhan, PhD, Matthew S Squires, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2994.

https://doi.org/10.1182/blood.V116.21.2994.2994

Published: 2010

Journal Articles

Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells.

Michal Bar-Natan, M.D, Erik A. Nelson, PhD, Sarah R. Walker, Ph.D., Rosemary Barrett, B.S., David A. Frank, MD, PhD

Blood (2009) 114 (22): 1905.

https://doi.org/10.1182/blood.V114.22.1905.1905

Published: 2009

Journal Articles

Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells.

Erik A. Nelson, PhD, Sarah R. Walker, Ph.D., Alicia Kepich, B.S., Shariya Terrell, B.S., Laurie Gashin, B.S., David A. Frank, M.D., Ph.D.

Blood (2007) 110 (11): 2953.

https://doi.org/10.1182/blood.V110.11.2953.2953

Published: 2007

Journal Articles

Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma.

Erik A. Nelson, PhD, Teru Hideshima, M.D. Ph.D, Laurie Gashin, Sarah R. Walker, B.S., Rebecca A. Lynch, B.S., Dharminder Chauhan, Ph.D., Kenneth C. Anderson, M.D., David A. Frank, M.D.,Ph.D.

Blood (2006) 108 (11): 3450.

https://doi.org/10.1182/blood.V108.11.3450.3450

Published: 2006

Journal Articles

IL-2 Therapy Promotes the Expansion of Human CD4+CD25+ Regulatory T Cells and Selectively Upregulates the Expression of FOXP3 in T Cells In Vivo.

Emmanuel Zorn, PhD, Erik A. Nelson, PhD, Mehrdad Mohseni, MD, Despina Litsa, BSc, Haesook Kim, PhD, Roberto Bellucci, PhD, Fabrice Porcheray, PharmD, Christine Canning, MD, Robert J. Soiffer, MD, Jerome Ritz, MD

Blood (2005) 106 (11): 1257.

https://doi.org/10.1182/blood.V106.11.1257.1257

Published: 2005

NARROW

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells.

Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells.

Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma.

IL-2 Therapy Promotes the Expansion of Human CD4+CD25+ Regulatory T Cells and Selectively Upregulates the Expression of FOXP3 in T Cells In Vivo.

Email alerts

ASH Publications

American Society of Hematology

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells.

Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells.

Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma.

IL-2 Therapy Promotes the Expansion of Human CD4+CD25+ Regulatory T Cells and Selectively Upregulates the Expression of FOXP3 in T Cells In Vivo.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only